Skip to main content
. 2024 Jan 17;12(1):101214. doi: 10.1016/j.gendis.2024.101214

Figure 2.

Figure 2

IGF2BP1 promotes the proliferation and cell cycle progression of HMCLs. (A, B) In the IGF2BP1-OE group, the ratio of EdU-positive cells was significantly higher. In the IGF2BP1-KD group, the ratio of EdU-positive cells was significantly lower. The percentages of EdU-positive cells were calculated from five randomly selected view regions of each slide. (C, D) Overexpression of IGF2BP1 promoted cell cycle progression by increasing the proportion of the S phase. Knockdown of IGF2BP1 inhibited RPMI-RPMI-8226 cell cycle progression by decreasing the proportion of the S phase in the cell cycle. Representative flow profiles of three independent experiments are shown, and the percentages of NCI-H929 cells at G0/G1, G2/M, and S phases were summarized. (E) The proliferation of NCI-H929 cells of the IGF2BP1-OE group and RPMI-RPMI-8226 cells of the IGF2BP1-KD group and NC group were determined by CCK8 assays at the indicated culture durations. (F) IGF2BP1-KD NCI-H929 cells showed a significantly higher multinucleation rate than the control cells. Representative images of DAPI staining are shown (red arrows indicate multinucleation), and the numbers of nuclei per cell were summarized. (G) IGF2BP1-OE NCI-H929 cells resulted in a ∼2.13-fold increase in tumor volume, relative to IGF2BP1-NC cells at day 21 after inoculation into B-NDG mice. IGF2BP1, insulin-like growth factor 2 mRNA binding protein 1; HMCLs, human multiple myeloma cell lines.